Internal Medicine, Endocrinology, Diabetes, & Metabolism · Greenville, NC
NPI
1629073010
Since 2005
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
1006 Wh Smith Blvd
Greenville, NC, 27834
Phone (252) 413-6683
Groups this clinician bills Medicare through
Medicare paid, 2024
$835K
55,297 services
Medicare patients, 2024
925
Average age 74
Drug cost, 2024
$5.1M
12,505 prescriptions
Company payments, 2025
$128K
From 33 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mark Warren was code J0897 (injection, denosumab, 1 mg), 6,660 times for 62 patients. In total Mark Warren billed 55,297 services in 122 codes, and Medicare paid $835K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2015-06-29.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 6,660 | 62 | $20.55 | $137K |
| 99214 Office E&M - Established | Office | 1,101 | 584 | $90.40 | $100K |
| 83036 Blood Count | Office | 837 | 394 | $9.52 | $7,968 |
| 36415 Venipuncture Blood Collection | Office | 702 | 456 | $8.64 | $6,065 |
| 82962 Clinical Chemistry | Office | 647 | 348 | $3.21 | $2,076 |
| 84443 Clinical Chemistry | Office | 581 | 420 | $16.44 | $9,550 |
| 84439 Clinical Chemistry | Office | 571 | 419 | $8.83 | $5,043 |
| 80053 Clinical Chemistry | Office | 536 | 369 | $10.33 | $5,539 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 509 | 360 | $12.11 | $6,162 |
| 95251 Test - Miscellaneous | Office | 481 | 193 | $25.41 | $12K |
| 99457 E&M - Miscellaneous | Office | 459 | 90 | $34.98 | $16K |
| 80061 Clinical Chemistry | Office | 370 | 281 | $13.12 | $4,854 |
| 99215 Office E&M - Established | Office | 307 | 220 | $128.28 | $39K |
| 99458 E&M - Miscellaneous | Office | 288 | 71 | $28.26 | $8,138 |
| 77080 Standard X-ray | Office | 271 | 271 | $17.72 | $4,803 |
By year: 2022 $496K for 34,064 services; 2023 $547K for 46,386 services; 2024 $835K for 55,297 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83036 Blood Count | 837 | 394 | $9.52 | $7,968 |
| 36415 Venipuncture Blood Collection | 702 | 456 | $8.64 | $6,065 |
| 82962 Clinical Chemistry | 647 | 348 | $3.21 | $2,076 |
| 84443 Clinical Chemistry | 581 | 420 | $16.44 | $9,550 |
| 84439 Clinical Chemistry | 571 | 419 | $8.83 | $5,043 |
| 80053 Clinical Chemistry | 536 | 369 | $10.33 | $5,539 |
| 80061 Clinical Chemistry | 370 | 281 | $13.12 | $4,854 |
| 85025 Blood Count | 226 | 175 | $7.59 | $1,716 |
| 81001 Clinical Chemistry | 212 | 170 | $3.10 | $658 |
| 82043 Clinical Chemistry | 169 | 151 | $5.65 | $956 |
Medicare prescription drug claims, 2024
In 2024, the drug Mark Warren prescribed most often to Medicare patients was Ozempic (Semaglutide), with 821 prescriptions and refills. In total Mark Warren wrote 12,505 Medicare prescriptions that cost $5.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 821 | 1,107 | 135 | $1.0M |
| Levothyroxine Sodium Generic | 696 | 1,675 | 175 | $7,257 |
| Metformin Hcl Er Metformin Hcl | 335 | 866 | 91 | $4,480 |
| Atorvastatin Calcium Generic | 327 | 792 | 90 | $3,070 |
| Tresiba Flextouch U-200 Insulin Degludec | 261 | 348 | 49 | $337K |
| Synthroid Levothyroxine Sodium | 260 | 533 | 52 | $23K |
| Amlodipine Besylate Generic | 241 | 517 | 53 | $1,834 |
| Tresiba Flextouch U-100 Insulin Degludec | 237 | 336 | 60 | $132K |
| Trulicity Dulaglutide | 235 | 303 | 35 | $289K |
| Rosuvastatin Calcium Generic | 231 | 611 | 66 | $2,524 |
| Glimepiride Generic | 228 | 605 | 65 | $2,174 |
| Jardiance Empagliflozin | 226 | 362 | 45 | $206K |
| Pioglitazone Hcl Generic | 209 | 505 | 57 | $3,442 |
| Metformin Hcl Generic | 183 | 450 | 46 | $1,690 |
| Simvastatin Generic | 178 | 452 | 46 | $1,700 |
Brand drugs: 5,463 claims; generic drugs: 6,314 claims; opioid claims: 105.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mark Warren $128K ($128K in general payments such as food, travel and fees) from 33 companies. The largest payer was Ascendis Pharma Endocrinology Inc with $87K.
| Company | Payments | Amount |
|---|---|---|
| Ascendis Pharma Endocrinology Inc ASND | 93 | $87K |
| Amgen Inc. AMGN | 42 | $25K |
| Abbott Laboratories ABT | 19 | $8,135 |
| Lilly USA, LLC LLY | 8 | $5,467 |
| Senseonics, Incorporated SENS | 2 | $800 |
| Intra-Sana Laboratories | 3 | $190 |
| Sequel Med Tech, LLC | 1 | $186 |
| Novo Nordisk Inc NVO | 6 | $179 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 1 | $109 |
| CeQur Corporation | 1 | $103 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.